Status:
COMPLETED
A Study of LY900020 in Healthy Chinese Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-70 years
Phase:
PHASE1
Brief Summary
This study will evaluate three new formulations of LY900020; a fixed dose, combination drug developed for people with type 2 diabetes mellitus. The study will be conducted in healthy participants to i...
Eligibility Criteria
Inclusion
- Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)
- Have a body mass index (BMI) of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, at screening
- Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study
Exclusion
- Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
- Have previously participated or withdrawn from this study
- Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Had blood loss of more than 400 milliliters (mL) within the last 3 months
Key Trial Info
Start Date :
November 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04047940
Start Date
November 29 2019
End Date
February 18 2020
Last Update
March 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623